Literature DB >> 3878367

Estimation of bone turnover evaluated by 47Ca-kinetics. Efficiency of serum bone gamma-carboxyglutamic acid-containing protein, serum alkaline phosphatase, and urinary hydroxyproline excretion.

P Charles, J W Poser, L Mosekilde, F T Jensen.   

Abstract

Bone gamma-carboxyglutamic acid-containing (Gla) protein (BGP, osteocalcin) is a noncollagenous protein of bone present in plasma and removed by the kidney. Plasma BGP has been shown to be elevated in patients with certain bone diseases. The present study evaluates serum BGP (S-BGP), serum alkaline phosphatase (S-AP), and urinary hydroxyproline excretion (U-OHP) in diseases with differing bone turnover rates, and compares the accuracy of these measurements for estimating bone mineralization (m) and resorption (r) rates. S-BGP, S-AP, U-OHP, and creatinine clearance (Clcr) were measured in patients with primary hyperparathyroidism (n = 13), hyperthyroidism (n = 6), and hypothyroidism (n = 6). Bone mineralization and resorption rates were calculated from a 7-d combined calcium balance and 47Ca turnover study. A highly significant correlation (r = 0.69, P less than 0.001) was found between S-BGP and m. Multiple regression analysis disclosed a partial correlation between S-BGP and m when Clcr was taken into account (r = 0.82, P less than 0.001), and between S-BGP and Clcr when m was taken into account (r = -0.62, P less than 0.005). In accordance with this, a stronger correlation (r = 0.89, P less than 0.0001) was found between S-BGP X Clcr and m than between S-BGP and m. A less significant correlation was found between S-AP and m (r = 0.45, P less than 0.05). Furthermore, U-OHP showed a highly significant positive correlation to r (r = 0.78, P less than 0.001). Thus, in the studied disorders of calcium metabolism, individual serum levels of BGP depend on both mineralization rate and renal function. Serum levels of BGP corrected for alterations in renal function are superior to uncorrected S-BGP and to S-AP levels in the estimation of bone mineralization rates.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3878367      PMCID: PMC424348          DOI: 10.1172/JCI112234

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  19 in total

1.  CORRELATION OF URINARY HYDROXYPROLINE, SERUM ALKALINE PHOSPHATASE AND SKELETAL CALCIUM TURNOVER.

Authors:  L KLEIN; F W LAFFERTY; O H PEARSON; P H CURTISS
Journal:  Metabolism       Date:  1964-03       Impact factor: 8.694

2.  Characterization of a gamma-carboxyglutamic acid-containing protein from bone.

Authors:  P A Price; A A Otsuka; J W Poser; J Kristaponis; N Raman
Journal:  Proc Natl Acad Sci U S A       Date:  1976-05       Impact factor: 11.205

3.  Primary structure of the gamma-carboxyglutamic acid-containing protein from bovine bone.

Authors:  P A Price; J W Poser; N Raman
Journal:  Proc Natl Acad Sci U S A       Date:  1976-10       Impact factor: 11.205

4.  Clinical applications of urinary hydroxyproline determination.

Authors:  O Laitinen
Journal:  Acta Med Scand Suppl       Date:  1975

5.  A new method for calculating the accretion rate of bone calcium and some observations on the suitability of strontium-85 as a tracer for bone calcium.

Authors:  J Reeve; R Wootton; B Hesp
Journal:  Calcif Tissue Res       Date:  1976-04-20

6.  Bone turnover model based on a continuously expanding exchangeable calcium pool.

Authors:  L Burkinshaw; D H Marshall; C B Oxby; F W Spiers; B E Nordin; M M Young
Journal:  Nature       Date:  1969-04-12       Impact factor: 49.962

7.  Radioimmunoassay for the vitamin K-dependent protein of bone and its discovery in plasma.

Authors:  P A Price; S K Nishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1980-04       Impact factor: 11.205

8.  Secretion of the vitamin K-dependent protein of bone by rat osteosarcoma cells. Evidence for an intracellular precursor.

Authors:  S K Nishimoto; P A Price
Journal:  J Biol Chem       Date:  1980-07-25       Impact factor: 5.157

9.  Direct identification of the calcium-binding amino acid, gamma-carboxyglutamate, in mineralized tissue.

Authors:  P V Hauschka; J B Lian; P M Gallop
Journal:  Proc Natl Acad Sci U S A       Date:  1975-10       Impact factor: 11.205

10.  Morphometric and dynamic studies of bone changes in hypothyroidism.

Authors:  L Mosekilde; F Melsen
Journal:  Acta Pathol Microbiol Scand A       Date:  1978-01
View more
  24 in total

1.  Bone turnover during high dose inhaled corticosteroid treatment.

Authors:  N J Ali; S Capewell; M J Ward
Journal:  Thorax       Date:  1991-03       Impact factor: 9.139

Review 2.  Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls.

Authors:  Serge Cremers; Patrick Garnero
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  The increase in spinal bone density that occurs in response to fluoride therapy for osteoporosis is not maintained after the therapy is discontinued.

Authors:  J R Talbot; M M Fischer; S M Farley; C Libanati; J Farley; A Tabuenca; D J Baylink
Journal:  Osteoporos Int       Date:  1996       Impact factor: 4.507

4.  Efficacy of wheat germ lectin-precipitated alkaline phosphatase in serum as an estimator of bone mineralization rate: comparison to serum total alkaline phosphatase and serum bone Gla-protein.

Authors:  K Brixen; H K Nielsen; E F Eriksen; P Charles; L Mosekilde
Journal:  Calcif Tissue Int       Date:  1989-02       Impact factor: 4.333

5.  Effects of COLIA1 polymorphisms and haplotypes on perimenopausal bone mass, postmenopausal bone loss and fracture risk.

Authors:  N González-Bofill; L B Husted; T Harsløf; C L Tofteng; B Abrahamsen; P Eiken; P Vestergaard; B L Langdahl
Journal:  Osteoporos Int       Date:  2010-06-23       Impact factor: 4.507

6.  Acute effects of nasal salmon calcitonin on calcium and bone metabolism.

Authors:  G Thamsborg; S G Skousgaard; H Daugaard; S Schifter; G Kollerup; O H Sørensen
Journal:  Calcif Tissue Int       Date:  1993-10       Impact factor: 4.333

7.  Serum osteocalcin and bone isoenzyme alkaline phosphatase in growth hormone-deficient patients: dose-response studies with biosynthetic human GH.

Authors:  H K Nielsen; J O Jørgensen; K Brixen; J S Christiansen
Journal:  Calcif Tissue Int       Date:  1991-02       Impact factor: 4.333

8.  Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption.

Authors:  R Eastell; S P Robins; T Colwell; A M Assiri; B L Riggs; R G Russell
Journal:  Osteoporos Int       Date:  1993-09       Impact factor: 4.507

9.  Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis.

Authors:  P Szulc; P D Delmas
Journal:  Osteoporos Int       Date:  2008-07-16       Impact factor: 4.507

10.  Assessment of bone formation by biochemical markers in metabolic bone disease: separation between osteoblastic activity at the cell and tissue level.

Authors:  P Charles; C Hasling; L Risteli; J Risteli; L Mosekilde; E F Eriksen
Journal:  Calcif Tissue Int       Date:  1992-12       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.